



# SIDDS 2023

Seoul International Digestive Disease Symposium 2023

In Conjunction with the Annual Meeting of the Korean Society of Gastroenterology

April 8-9, 2023 Hybrid congress



<b>Name</b>	Young Youn Cho
<b>Affiliation</b>	Chung-Ang University Hospital
<b>Country</b>	Korea
<b>Major Field</b>	Hepatology

## Educational Background

2018 Ph.D. Candidate Seoul National University  
2015 Master degree Seoul National University  
2010 Bachelor degree Seoul National University

## Professional Experience

2018.3-Current Assistant Professor Chung-ang University Hospital  
2016.9-2018.1 Assistant Professor Seoul National University Hospital  
2015.3-2016.7 Fellow Seoul National University Hospital  
2011.3-2015.2 Resident Seoul National University Hospital  
2010.3-2011.2 Intern Seoul National University Hospital

## Other Experience and Professional Memberships

Member of The Korean Society of Gastroenterology.  
Member of Korean Association for the study of the Liver  
Member of The Korean Association of Internal medicine  
Member of The Asian Pacific Association for the Study of the Liver

## Main Scientific Publications

1. Co-First/ J Viral Hepat. 2018 Apr;25(4):412-420. / A direct role for hepatitis B virus X protein in inducing mitochondrial membrane permeabilization / Lee HR, Cho YY, Lee GY, You DG, Yoo YD, Kim YJ
2. First / J Viral Hepat. 2018 Oct;25(10):1161-1171. / Comparison of overall survival between antiviral-induced viral suppression and inactive phase chronic hepatitis B patients. / Cho YY, Lee JH, Chang Y, Nam JY, Cho H, Lee DH, Cho EJ, Lee DH, Yu SJ, Lee JM, Kim YJ, Yoon JH.
3. First / J Liver Cancer 2019 Sep 30; 19(2): 128-135. / Tenofovir and Entecavir has Similar Renal Adverse Events on Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization / Cho YY et al.
4. Co-First/ Biochim Biophys Acta Biomembr. 2019 Apr 1;1861(4):729-737 / Hepatitis B virus X protein induces size-selective membrane permeabilization through interaction with cardiolipin./ You DG, Cho YY, Lee HR, Lee JH, Yu SJ, Yoon JH, Yoo YD, Kim YJ, Lee GY.



# SIDDS 2023

Seoul International Digestive Disease Symposium 2023

In Conjunction with the Annual Meeting of the Korean Society of Gastroenterology

April 8-9, 2023 Hybrid congress



5. First/ *J Clin Gastroenterol.* 2020 Apr;54(4):370-377. / The Model to Estimate Survival in Ambulatory Hepatocellular Carcinoma Patients Aids in the Decision for TACE Retreatment. / Cho YY, Yu SJ, Yoo JJ, Lee M, Lee DH, Cho Y, Yoon KW, Cho EJ, Lee JH, Kim YJ, Yoon JH.
6. First / *Gut Liver.* 2020 Mar 15;14(2):225-231./ Long-term Nucleotide Analogue Treatment Has Higher Renal Toxicities than Entecavir in Patients with Chronic Hepatitis B / Cho YY, Chang Y, Nam JY, Cho H, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ.
7. First/*J Hepatocell Carcinoma.* 2021 Jun 18;8:613-623./Clinical Characteristics of Long-Term Survivors After Sorafenib Treatment for Unresectable Hepatocellular Carcinoma: A Korean National Multicenter Retrospective Cohort Study./Cho YY, Yu SJ, Lee HW, Kim DY, Kang W, Paik YH, Sung PS, Bae SH, Park SC, Doh YS, Kim KM, Jang ES, Kim IH, Kim W, Kim YJ.
8. Co-First/ *J Hepatocell Carcinoma.* 2021 Jun 15;8:587-598./Effectiveness of Transarterial Chemoembolization-First Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis./Chung SW, Park MK, Cho YY, Park Y, Lee CH, Oh H, Jang H, Kim MA, Kim SW, Nam JY, Lee YB, Cho EJ, Yu SJ, Kim HC, Kim YJ, Chung JW, Yoon JH, Lee JH.
9. Co-First/ *Hepatol Int.* 2021 Oct;15(5):1083-1092 /Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B./Lee HW, Cho YY, Lee H, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK, Park SY.
10. Co-First / *J Viral Hepat.* 2021 Nov;28(11):1570-1578./ Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B. / Lee HW, Cho YY, Lee H, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK, Park SY.
11. Co-First / *Clin Mol Hepatol.* 2022 Jul;28(3):425-472. / Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases. / Lee HA, Chang Y, Sung PS, Yoon EL, Lee HW, Yoo JJ, Lee YS, An J, Song DS, Cho YY, Kim SU, Kim YJ.